On Monday, KBR, Inc. (NYSE:KBR)’s shares inclined 0.42% to $19.23.
KBR, Inc. (KBR) declared recently it has been awarded a near-shore floating LNG Front End Engineering Design (FEED) contract by Lloyds Energy Ltd.
Under this contract, KBR will provide integrated topsides and hull engineering design services for a nominal 2.5 million TPA floating natural gas liquefaction plant (FLNG). Start-up of the project facilities is predictable to take place in 2019.
All LNG processing facilities, together with the associated utilities and power generation, will be located on the FLNG barges, which will be moored at the end of a new single jetty, about 3.5km in length. LNG storage will be in the barge hulls and loading will be via a separate LNG carrier berth at the end of the jetty.
KBR, Inc. operates as an engineering, construction, and services company worldwide. The company operates through three segments: Technology & Consulting, Engineering & Construction, and Government Services. The Technology & Consulting segment offers various services and solutions, counting licensing, engineering and design, proprietary equipment, plant automation, catalysts, and related consulting services to hydrocarbons, chemicals, and fertilizer markets.
Idera Pharmaceuticals Inc (NASDAQ:IDRA)’s shares dropped -6.77% to $3.58.
Idera Pharmaceuticals Inc (IDRA) declared that Vincent Milano, Idera’s Chief Executive Officer will present a corporate update at the Jefferies 2015 Global Healthcare Conference on Monday, June 1, 2015 at 1:30 p.m. Eastern Time at the Grand Hyatt in New York City.
Mr. Milano will also be presenting at the 9th Annual JMP Securities Healthcare Conference on Wednesday, June 24, 2015 at 12:30 p.m. Eastern Time at the St. Regis Hotel in New York City.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States. It uses two proprietary drug discovery technology platforms to design and develop drug candidates, counting toll-like receptor targeting technology and gene silencing oligonucleotide (GSO) technology.
At the end of Monday’s trade, IsoRay, Inc. (NYSEMKT:ISR)‘s shares dipped -7.50% to $1.66.
IsoRay, Inc. (ISR) declared that a number of industry leaders talk about the successes achieved by their patients in a variety of body sites being treated with IsoRay’s Cesium-131 internal radiation (brachytherapy) cancer seeds at the “Advances in Brachytherapy” symposium, held at Weill Cornell on Friday and Saturday.
soRay, Inc develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States.
Zulily Inc (NASDAQ:ZU), ended its Monday’s trading session with -1.47% loss, and closed at $13.03.
Zulily Inc (ZU) declared that Darrell Cavens, President and Chief Executive Officer, and Brian Swartz, Chief Financial Officer, will take part in the following investor conferences:
- Wednesday, June 10, 2015 at 10:00 a.m. CT — Mr. Cavens will present at the William Blair Growth Stock Conference in Chicago, IL.
- Thursday, June 18, 2015 at 10:30 a.m. ET — Mr. Cavens will take part in a question-and-answer session at the Goldman Sachs dotCommerce Day in New York, NY.
zulily, inc. operates as an online retailer in the United States, Canada, Australia, the United Kingdom, and internationally. The company provides merchandise to moms purchasing for their children, themselves, and their homes.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
